NCT06715683

A Study to Evaluate Comparative Bioavailability of BMS-986278 in Healthy Participants

An Open-label, Randomized, 2-Part, 4-Period, 2-Sequence, Fully Replicated Crossover Study to Assess the Comparative Bioavailability of BMS-986278 To-be-marketed Formulation Compared to the Phase 3 Clinical Trial Formulation in Healthy Participants

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 48 (actual)
• Sponsor: Bristol-Myers Squibb · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

This is a trial to evaluate the comparative bioavailability of BMS-986278 to-be-marketed formulation compared to the phase 3 clinical trial formulation in healthy participants.

Conditions

• Healthy Volunteers

Interventions

Type	Name	Description
DRUG	BMS-986278 Batched method, Dose A	Specified dose on specified days
DRUG	BMS-986278 Batched method, Dose B	Specified dose on specified days
DRUG	BMS-986278 Continuous method	Specified dose on specified days

Timeline

• Start date: 2024-12-12
• Primary completion: 2025-03-16
• Completion: 2025-03-16
• First posted: 2024-12-04
• Last updated: 2025-04-04

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study